Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Sanofi’s BTK in­hibitor rilz­abru­ti­nib helped 23% of adults with a rare au­toim­mune blood dis­or­der achieve tar­get platelet counts in a Phase 3 tri­al, com­pared to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER